Please assess the completion status of the following clinical trial:

Trial Title: Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
FOR SCREENING PHASE:~Inclusion Criteria:~1. Diagnosis of extranodal NK/T lymphoma, per WHO classification, 4th ed., which must include EBV tumor positivity, measured either by EBV encoded RNA (EBER) or LMP1 immunostaining.~2. a) Active Disease~(1) Clinically suspected or documented relapse/progression, in first or second relapse following at least one cycle of an asparaginase-based chemotherapy regimen OR (2) Initial disease or first or second relapse and unable to tolerate one full cycle of asparaginase-based chemotherapy regimen OR b) High-risk disease (stage III/IV, KPI groups 3-4 or IPI intermediate-high) prior to second CR regardless of previous chemotherapy.~3. Male or female ≥ 18 years of age. 4. Weigh ≥ 35 kg. 5. ECOG performance score 0-2, inclusively. 6. Negative β-hCG test in women of childbearing potential. 7. Able to understand and comply with the requirements of the study and to provide written informed consent.~Exclusion Criteria:~1. CNS lymphoma.~2. NK cell leukemia.~3. Hemophagocytic lymphohistiocytosis.~4. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T Cell leukemia virus (HTLV).~5. Use of systemic corticosteroids \>0.5 mg/kg/day within 10 days prior to obtaining 200 mL whole blood starting material.~6. Patient is pregnant or lactating.~7. Active second malignancy.~8. Any prior allogeneic hematopoietic stem cell or solid organ transplant.~9. Asparaginase refractory disease, defined by any one of the following:~   1. Progression at any time during initial asparaginase based chemotherapy and up to 3 months after end of initial asparaginase based chemotherapy, OR~  2. Failure to achieve at least PR with initial asparaginase based chemotherapy.~10. Absolute lymphocyte count (ALC) \<400/µL.~11. Any previous autologous EBV specific T cell treatment.~12. Systemic fungal, bacterial, viral or other infection that is not controlled.~13. Third or greater relapse.~FOR TREATMENT PHASE:~Inclusion Criteria:~1. Documented relapse or progression following at least one prior cycle of an asparaginase-containing chemotherapy regimen.~2. Active disease based on any one of the following present at the baseline study visit or within two weeks prior to the baseline study visit:~   1. Imaging (may use local imaging)~  2. Clinical sign(s) including skin lesions consistent with lymphoma, organ dysfunction or organomegaly not attributable to other causes; or other clinical sign(s)~  3. Detectable blood or plasma ENV DNA (may use local laboratory)~3. Completed most recent course of chemotherapy at least 2 weeks prior to first study drug dose.~4. Recovery from acute hematological, hepatic and renal chemotherapy-related toxicities as defined by ≤ Grade 1 according to NCI CTCAE v4.0.~5. Life expectancy ≥ 8 weeks.~Exclusion Criteria:~1. Use of any investigational agents within prior 4 weeks.~2. Radiotherapy within prior 3 weeks.~3. Major surgery within prior 2 weeks.~4. Systemic corticosteroids within 24 hours prior to study drug administration.~5. Evidence of hepatic dysfunction based on serum total bilirubin \>3 times upper limit of normal (ULN), or ALT \>5 times ULN or AST \>5 times ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- baltaleucel-T (Type: EXPERIMENTAL): Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).